Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
<p>Response criteria represent the standard by which the efficacy of therapeutic agents is determined in cancer trials. The most widely used criteria are based on the anatomic measurement of solid tumors. Because bone metastases are typically located in irregularly shaped bones and are difficu...
Main Author: | Colleen M. Costelloe, Hubert H. Chuang, John E. Madewell, Naoto T. Ueno |
---|---|
Format: | Article |
Language: | English |
Published: |
Ivyspring International Publisher
2010-01-01
|
Series: | Journal of Cancer |
Online Access: | http://www.jcancer.org/v01p0080.htm |
Similar Items
-
Comparison between RECIST and PERCIST criteria in therapeutic response assessment in cases of lymphoma
by: Marwa Mohammed Hasan Tawfik, et al.
Published: (2020-05-01) -
Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis
by: Hong Deok Kim, et al.
Published: (2019-05-01) -
RECIST 1.1 CRITERIA IN THE ASSESSMENT OF LUNG TUMORS
by: O. N. Chernova, et al.
Published: (2017-03-01) -
PET/CT implication on bronchogenic carcinoma TNM staging and follow-up using RECIST/PERCIST criteria: a comparative study with CT
by: Ahmed M. Osman, et al.
Published: (2020-01-01) -
Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy
by: Cory Pierson, et al.
Published: (2018-02-01)